Corcept Therapeutics

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 15, 2022
NASDAQ, CORT, Income, Amyotrophic lateral sclerosis, Irritability, GRACE, Intellectual property, Patient, Mifepristone, Food, GAAP, Depression, Cushing's syndrome, Neck, Ovarian cancer, SEC, Weight gain, Enrollment, Fatty liver disease, Goal, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lists of diseases, Intention, ALS, NASH, MD, Insurance, Liver, Diabetes, FDA, Survival, Mission statement, Sale, Â, Ageing, Fatigue, Liver disease, NDA, Overalls, Growth, Investment, COVID-19, Microdeletion syndrome, Investor, Metabolic disorder, Doctor of Pharmacy, GLOBE, Muscle, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Video game, Lithium, Corcept Therapeutics

Corcepts fourth quarter 2021 revenue was $98.8 million, compared to $85.7 million in the fourth quarter of 2020.

Key Points: 
  • Corcepts fourth quarter 2021 revenue was $98.8 million, compared to $85.7 million in the fourth quarter of 2020.
  • GAAP net income was $32.1 million in the fourth quarter of 2021, compared to $26.0 million in the fourth quarter of 2020.
  • For the full year, it was $112.5 million in 2021, compared to $106.0 million in 2020.
  • Cash and investments of $335.8 million at December 31, 2021 reflects the purchase of ten million shares of Corcept common stock for $207.5 million in the fourth quarter 2021.

Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, February 12, 2022
NASDAQ, CORT, Medal, Record, Corcept Therapeutics, Health Insurance Portability and Accountability Act, Company, District, U.S. Department of Justice Office of Legislative Affairs, CDNA, SEC, Privacy Office of the U.S. Department of Homeland Security, U.S. Securities and Exchange Commission, Therapy, Sale, DOJ, HIPAA, Accountability Act, Alpha, HuffPost, News, GLOBE, Online gambling, Animal, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Agrifys common stock price fell sharply during intraday trading on December 16, 2021.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on: 
Tuesday, February 8, 2022
NASDAQ, Liver disease, Corcept Therapeutics, GLOBE, Investor, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Weight gain, Ovarian cancer, Food, CORT, Patient, Pharmaceutical industry

MENLO PARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022.

Key Points: 
  • MENLO PARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022.
  • The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
  • Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call.
  • Corcepts approved medication, Korlym, was the first drug approved by the U.S. Food and Drug Administration for patients with Cushings syndrome.

SHAREHOLDER ALERT: Morris Kandinov Investigating QS, RMO, XELA, and CORT; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Monday, February 7, 2022
Corcept Therapeutics, GLOBE, News, District court, Morgan Stanley, Company, Health Insurance Portability and Accountability Act, Therapy, Sale, QuantumScape, Technology, District, Accountability Act, U.S. Securities and Exchange Commission, SEC, Life, Record, Cell, SAN, Online gambling

Morris Kandinov is investigating QuantumScape regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.

Key Points: 
  • Morris Kandinov is investigating QuantumScape regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Morris Kandinov is investigating Romeo regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Morris Kandinov is investigating Exela regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Morris Kandinov is investigating Corcept regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Agrify, Affirm Holdings, and Medallion Financial and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, February 7, 2022
NASDAQ, Corcept Therapeutics, GLOBE, News, Consumer Financial Protection Bureau, Company, Health Insurance Portability and Accountability Act, Sale, District, CFPB, Accountability Act, HuffPost, U.S. Securities and Exchange Commission, CORT, SEC, Medal, Alpha, Record, Consumer, HIPAA, Online gambling, Animal, Audit, Security (finance), P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Medallion Financial investigation go to: https://bespc.com/cases/MFIN
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDX, Medallion, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 1, 2022
District, CDNA, Health Insurance Portability and Accountability Act, Therapy, HIPAA, U.S. Securities and Exchange Commission, NASDAQ, Sale, CORT, HuffPost, SEC, U.S. Department of Justice Office of Legislative Affairs, DOJ, Alpha, Company, Medal, Corcept Therapeutics, GLOBE, News, Privacy Office of the U.S. Department of Homeland Security, Accountability Act, Record, Online gambling, Animal, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Agrifys common stock price fell sharply during intraday trading on December 16, 2021.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Cronos, Everbridge, and Hollysys and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, January 27, 2022
CEO, Record, LLP, Ernst & Young, Annual report, Stifel, U.S. Securities and Exchange Commission, Form 10-Q, CORT, Accountability Act, Sale, Everbridge, Bloomberg, HIPAA, NASDAQ, Therapy, Mission statement, Company, Exchange, Corcept Therapeutics, News, District, GLOBE, Health Insurance Portability and Accountability Act, Online gambling, Animal, Audit, Cronos, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Corcepts stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.
  • For more information on the Hollysys investigation go to: https://bespc.com/cases/HOLI
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT)

Retrieved on: 
Tuesday, January 25, 2022
Legal, Professional Services, Lists of diseases, Therapy, News, USAO, Record, Accountability Act, NASDAQ, Company, Corcept Therapeutics, District, Sale, HIPPA, Health Insurance Portability and Accountability Act, CORT, Pharmaceutical industry, Medical device

Shareholder rights law firm Robbins LLP is investigating the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the securities laws.

Key Points: 
  • Shareholder rights law firm Robbins LLP is investigating the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the securities laws.
  • Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders.
  • If you would like more information about Corcept Therapeutics Incorporated's misconduct, click here .
  • If you own shares of Corcept Therapeutics Incorporated, contact us to learn more about your rights.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT

Retrieved on: 
Sunday, January 23, 2022
U.S. Securities and Exchange Commission, Corcept Therapeutics, Accountability Act, News, Health Insurance Portability and Accountability Act, CORT, Pomerantz, Record, NASDAQ, Company, LLP, GLOBE, HIPAA, District, Sale, Private investigator

NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ:CORT).

Key Points: 
  • NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ:CORT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Is Investigating Natera, Nuvei, Corcept Therapeutics, and Agrify and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, January 22, 2022
U.S. Securities and Exchange Commission, Corcept Therapeutics, Patient, Accountability Act, News, Health Insurance Portability and Accountability Act, CORT, Record, NTRA, NASDAQ, GLOBE, Review, Time, Humboldt Hill, California, Company, Miscarriage, The New York Times, Hash-based cryptography, HIPAA, District, Sale, Online gambling, Audit, Silviculture, Animal, Natera, Nuvei, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Nateras stock declined as much as 3.5% during intraday trading on January 3, 2022, thereby injuring investors.
  • For more information on the Agrify investigation go to: https://bespc.com/cases/AGFY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.